

Alexei V Tulin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2211799/publications.pdf>

Version: 2024-02-01

34
papers

1,998
citations

377584

21
h-index

445137

33
g-index

34
all docs

34
docs citations

34
times ranked

2241
citing authors

#	ARTICLE	IF	CITATIONS
1	Poly(ADP-ribosyl)ating pathway regulates development from stem cell niche to longevity control. <i>Life Science Alliance</i> , 2022, 5, e202101071.	1.3	5
2	PARG suppresses tumorigenesis and downregulates genes controlling angiogenesis, inflammatory response, and immune cell recruitment. <i>BMC Cancer</i> , 2022, 22, 557.	1.1	4
3	Poly(ADP)-Ribosylation Inhibition: A Promising Approach for Clear Cell Renal Cell Carcinoma Therapy. <i>Cancers</i> , 2021, 13, 4973.	1.7	10
4	Age-Related Changes of Gene Expression Profiles in <i>Drosophila</i> . <i>Genes</i> , 2021, 12, 1982.	1.0	8
5	Poly(ADP-ribose) polymerase 1 in genome-wide expression control in <i>Drosophila</i> . <i>Scientific Reports</i> , 2020, 10, 21151.	1.6	9
6	Novel allosteric PARP1 inhibitors for the treatment of BRCA-deficient leukemia. <i>Medicinal Chemistry Research</i> , 2020, 29, 962-978.	1.1	4
7	Structurally unique PARP1 inhibitors for the treatment of prostate cancer. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00586.	1.1	2
8	Hit and run versus long-term activation of PARP-1 by its different domains fine-tunes nuclear processes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 9941-9946.	3.3	63
9	Non-NAD-like PARP-1 inhibitors in prostate cancer treatment. <i>Biochemical Pharmacology</i> , 2019, 167, 149-162.	2.0	21
10	Non-NAD-like PARP1 inhibitor enhanced synthetic lethal effect of NAD-like PARP inhibitors against BRCA1-deficient leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 1098-1101.	0.6	12
11	PARP-1 Interaction with and Activation by Histones and Nucleosomes. <i>Methods in Molecular Biology</i> , 2017, 1608, 255-267.	0.4	0
12	High-Throughput Colorimetric Assay for Identifying PARP-1 Inhibitors Using a Large Small-Molecule Collection. <i>Methods in Molecular Biology</i> , 2017, 1608, 299-312.	0.4	3
13	Non-NAD-Like poly(ADP-Ribose) Polymerase-1 Inhibitors effectively Eliminate Cancer in vivo. <i>EBioMedicine</i> , 2016, 13, 90-98.	2.7	38
14	Poly(ADP-Ribosyl)ation of hnRNP A1 Protein Controls Translational Repression in <i>Drosophila</i> . <i>Molecular and Cellular Biology</i> , 2016, 36, 2476-2486.	1.1	10
15	Bookmarking promoters in mitotic chromatin: poly(ADP-ribose)polymerase-1 as an epigenetic mark. <i>Nucleic Acids Research</i> , 2014, 42, 7028-7038.	6.5	56
16	Kinase-Mediated Changes in Nucleosome Conformation Trigger Chromatin Decondensation via Poly(ADP-Ribosyl)ation. <i>Molecular Cell</i> , 2014, 53, 831-842.	4.5	39
17	Minor groove binding ligands disrupt PARP-1 activation pathways. <i>Oncotarget</i> , 2014, 5, 428-437.	0.8	22
18	Poly-ADP-ribose polymerase: Machinery for nuclear processes. <i>Molecular Aspects of Medicine</i> , 2013, 34, 1124-1137.	2.7	71

#	ARTICLE	IF	CITATIONS
19	Post-Transcriptional Regulation by Poly(ADP-ribosyl)ation of the RNA-Binding Proteins. International Journal of Molecular Sciences, 2013, 14, 16168-16183.	1.8	56
20	Poly(ADP-Ribose) Polymerase 1 (PARP-1) Regulates Ribosomal Biogenesis in Drosophila Nucleoli. PLoS Genetics, 2012, 8, e1002442.	1.5	85
21	Poly(ADP-ribose) controls DE-cadherin-dependent stem cell maintenance and oocyte localization. Nature Communications, 2012, 3, 760.	5.8	48
22	Re-evaluating PARP1 inhibitor in cancer. Nature Biotechnology, 2011, 29, 1078-1079.	9.4	18
23	<i>Drosophila</i> histone H2A variant (H2Av) controls poly(ADP-ribose) polymerase 1 (PARP1) activation in chromatin. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 6205-6210.	3.3	61
24	Small-Molecule Collection and High-Throughput Colorimetric Assay to Identify PARP1 Inhibitors. Methods in Molecular Biology, 2011, 780, 491-516.	0.4	13
25	Uncoupling of the transactivation and transrepression functions of PARP1 protein. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 6406-6411.	3.3	54
26	The roles of PARP1 in gene control and cell differentiation. Current Opinion in Genetics and Development, 2010, 20, 512-518.	1.5	126
27	Poly(ADP-ribosyl)ation of heterogeneous nuclear ribonucleoproteins modulates splicing. Nucleic Acids Research, 2009, 37, 3501-3513.	6.5	84
28	Poly (ADP-Ribose) Polymerase 1 Is Required for Protein Localization to Cajal Body. PLoS Genetics, 2009, 5, e1000387.	1.5	71
29	Nucleosome-binding affinity as a primary determinant of the nuclear mobility of the pioneer transcription factor FoxA. Genes and Development, 2009, 23, 804-809.	2.7	190
30	Nucleosomal Core Histones Mediate Dynamic Regulation of Poly(ADP-ribose) Polymerase 1 Protein Binding to Chromatin and Induction of Its Enzymatic Activity. Journal of Biological Chemistry, 2007, 282, 32511-32519.	1.6	96
31	Drosophila Poly(ADP-Ribose) Glycohydrolase Mediates Chromatin Structure and SIR2-Dependent Silencing. Genetics, 2006, 172, 363-371.	1.2	53
32	Chromatin Loosening by Poly(ADP)-Ribose Polymerase (PARP) at Drosophila Puff Loci. Science, 2003, 299, 560-562.	6.0	426
33	Regulation of Chromatin Structure and Gene Activity by Poly(ADP-Ribose) Polymerases. Current Topics in Developmental Biology, 2003, 56, 55-83.	1.0	53
34	The Drosophila heterochromatic gene encoding poly(ADP-ribose) polymerase (PARP) is required to modulate chromatin structure during development. Genes and Development, 2002, 16, 2108-2119.	2.7	187